CTLA4 and cancer: Immune-checkpoint inhibitors, such as anti-PD1/PD-L1 and anti-CTLA4, have been shown to activate the host immune response and have been approved for the treatment of multiple types of cancer.[40–43] The expression of immune checkpoints increased in the high-risk group of both the CRGs and Cr-lncRNAs models.